GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Short Interest

Oncolytics Biotech (TSX:ONC) Short Interest


View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Oncolytics Biotech's Short Interest

For the Biotechnology subindustry, Oncolytics Biotech's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Short Interest distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Short Interest falls into.


;
;

Oncolytics Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Short Interest
Comparable Companies
XCNQ:ONCO TSX:MDNA TSXV:MIR TSXV:COV TSX:MBX XCNQ:DTC TSX:MSCL XCNQ:GLAB TSXV:SHRX TSX:SVA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ONCY:USA
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Website
https://www.oncolyticsbiotech.com
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Executives
Angela Frances Holtham Director
Deborah Brown Director
Bernd Robert Seizinger Director
Matthew Coffey Director, Senior Officer
Kirk Look Senior Officer